米卡多毛孢菌不易受棘白菌素类抗真菌药物的影响。
Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.
机构信息
Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases' CE Rotterdam, The Netherlands.
出版信息
Antimicrob Agents Chemother. 2010 Jun;54(6):2738-40. doi: 10.1128/AAC.01546-09. Epub 2010 Mar 29.
Abstract
Eumycetoma caused by Madurella mycetomatis is treated surgically and with high doses of ketoconazole. Therapeutic responses are poor, and recurrent infections are common. In search of therapeutic alternatives in the treatment of mycetoma, we determined the in vitro susceptibilities of M. mycetomatis isolates against caspofungin, anidulafungin, and micafungin. As a comparator fungus, Aspergillus fumigatus was used. Minimal effective concentrations (MECs) and MICs were assessed and compared to those of ketoconazole. M. mycetomatis isolates were not susceptible to the echinocandins.
摘要
由节荚孢霉引起的外斐氏菌病采用手术和大剂量酮康唑治疗。治疗反应不佳，且常复发感染。为了寻找治疗外斐氏菌病的替代方法，我们测定了节荚孢霉分离株对卡泊芬净、阿尼芬净和米卡芬净的体外敏感性。曲霉菌被用作对照真菌。评估并比较了最小有效浓度（MEC）和 MIC 与酮康唑的 MIC。节荚孢霉分离株对棘白菌素类药物不敏感。
相似文献
1
Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.
Antimicrob Agents Chemother. 2010 Jun;54(6):2738-40. doi: 10.1128/AAC.01546-09. Epub 2010 Mar 29.
2
In vitro antifungal activity of isavuconazole against Madurella mycetomatis.
Antimicrob Agents Chemother. 2012 Nov;56(11):6054-6. doi: 10.1128/AAC.01170-12. Epub 2012 Sep 10.
3
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. doi: 10.1128/AAC.00699-07. Epub 2007 Oct 15.
4
Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
Antimicrob Agents Chemother. 2012 Mar;56(3):1215-22. doi: 10.1128/AAC.05872-11. Epub 2011 Dec 27.
5
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
Antimicrob Agents Chemother. 2011 Aug;55(8):3944-6. doi: 10.1128/AAC.00428-11. Epub 2011 Jun 13.
6
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02045-16. Print 2017 Mar.
7
In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.
J Clin Microbiol. 2009 Oct;47(10):3323-5. doi: 10.1128/JCM.01155-09. Epub 2009 Aug 26.
8
Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Clin Microbiol Infect. 2009 Mar;15(3):274-9. doi: 10.1111/j.1469-0691.2008.02660.x. Epub 2009 Feb 5.
9
Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.
Microbes Infect. 2007 Jul;9(9):1114-23. doi: 10.1016/j.micinf.2007.05.015. Epub 2007 May 18.
10
The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma.
PLoS Negl Trop Dis. 2021 Jun 9;15(6):e0009488. doi: 10.1371/journal.pntd.0009488. eCollection 2021 Jun.
引用本文的文献
1
Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma.
J Antimicrob Chemother. 2025 Apr 30;80(6):1733-41. doi: 10.1093/jac/dkaf133.
2
Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae044.
3
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0003423. doi: 10.1128/cmr.00034-23. Epub 2024 May 1.
4
The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad118.
5
In vitro susceptibility testing for black grain eumycetoma causative agents.
Trans R Soc Trop Med Hyg. 2021 Apr 14;115(4):343-354. doi: 10.1093/trstmh/traa184.
6
Development and Validation of an Resazurin-Based Susceptibility Assay against .
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01338-20.
7
Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1828-1834. doi: 10.1111/jdv.16402. Epub 2020 May 15.
8
Pyomelanin Secretion in Madurella mycetomatis Interferes with Spectrophotometric Endpoint Reading Using the Sensititre YeastOne alamarBlue Assay but Not with Visual Endpoint Reading.
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01532-19.
9
Pulmonary Scedosporium apiospermum Infection with Pulmonary Tumorlet in an Immunocompetent Patient.
Intern Med. 2018 Dec 1;57(23):3485-3490. doi: 10.2169/internalmedicine.1239-18. Epub 2018 Aug 10.
10
Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.
PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006437. doi: 10.1371/journal.pntd.0006437. eCollection 2018 Apr.
本文引用的文献
1
The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus.
Med Mycol. 2010 Feb;48(1):48-55. doi: 10.3109/13693780802713497.
2
Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae.
Antimicrob Agents Chemother. 2009 May;53(5):1772-8. doi: 10.1128/AAC.00020-09. Epub 2009 Mar 2.
3
Echinocandins: a wealth of choice--how clinically different are they?
Curr Opin Infect Dis. 2008 Aug;21(4):426-32. doi: 10.1097/QCO.0b013e328307c79c.
4
Resistance to echinocandin-class antifungal drugs.
Drug Resist Updat. 2007 Jun;10(3):121-30. doi: 10.1016/j.drup.2007.04.002. Epub 2007 Jun 13.
5
Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture.
Antimicrob Agents Chemother. 2006 Jun;50(6):2214-6. doi: 10.1128/AAC.01610-05.
6
Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size.
J Clin Microbiol. 2005 Sep;43(9):4349-56. doi: 10.1128/JCM.43.9.4349-4356.2005.
7
Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.
Antimicrob Agents Chemother. 2005 Jul;49(7):2851-6. doi: 10.1128/AAC.49.7.2851-2856.2005.
8
Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.
Antimicrob Agents Chemother. 2005 Apr;49(4):1364-8. doi: 10.1128/AAC.49.4.1364-1368.2005.
9
In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.
Antimicrob Agents Chemother. 2004 Jul;48(7):2742-6. doi: 10.1128/AAC.48.7.2742-2746.2004.
10
In vitro activity of anidulafungin against selected clinically important mold isolates.
Antimicrob Agents Chemother. 2004 May;48(5):1912-5. doi: 10.1128/AAC.48.5.1912-1915.2004.
Zotero 插件